Christine Potkay

Christine Potkay is an associate in Goodwin’s Intellectual Property Litigation practice who represents life sciences and technology companies in complex patent disputes across district courts, the International Trade Commission (ITC), and the Patent Trial and Appeal Board (PTAB). Christine also advises clients in arbitration matters arising from intellectual property licenses and commercial agreements and maintains an active pro bono practice.

Christine has experience across all stages of litigation, from pre-suit investigation through trial and appeal.

Her representative experience includes:

Hatch-Waxman and Life Sciences Litigation

• Representing Dr. Reddy’s Laboratories in patent infringement litigation concerning Dr. Reddy’s generic versions of Suboxone® (buprenorphine hydrochloride and naloxone hydrochloride) sublingual films
• Representing Teva in Hatch-Waxman litigation related to a generic version of a drug product for the treatment of ADHD

ITC and Technology Patent Litigation

• Representing Samsung in multiple ITC proceedings relating to electronic display technology and microwave-hood combination products

PTAB Proceedings and IP Strategy

• Representing clients in inter partes review proceedings involving life sciences and technology patents
• Advising clients on integrated litigation and PTAB strategies in high-stakes patent disputes, including strategy for filing and defending against PTAB challenges

Licensing, Arbitration, and Commercial IP Disputes

• Representing a biotech company in a breach of contract action arising from a license agreement
• Representing a biotech company in a high-stakes ICC arbitration initiated against a major global drug manufacturer relating to the parties’ product license and supply agreement

Pro Bono

Christine maintains an active pro bono practice, including working with the ACLU of Massachusetts and ACLU of Michigan to challenge policies and practices denying medication for the treatment of opioid use disorder (MOUD) to incarcerated people.

While attending law school, Christine was a judicial intern to the Honorable Jerome B. Simandle, U.S. District Judge for the District of New Jersey (Summer 2015) and the Honorable Michael A. Shipp, U.S. District Judge for the District of New Jersey (Spring 2017).

Christine is an editor of the Goodwin PTAB Trial Tracker periodic newsletter.

• Special Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S. 2023-2024 ed.,” published by Thomson Reuters, January 2024
• Special Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2022-2023 ed.,” published by Thomson Reuters, December 2022
• Special Contributor, "Guide to Biosimilars Litigation and Regulation in the U.S., 2021-2022 ed.," published by Thomson Reuters, October 2022
• Special Contributor, "Guide to Biosimilars Litigation and Regulation in the U.S., 2020-2021 ed.," published by Thomson Reuters, January 2021 
• Contributor, "Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed.," published by Thomson Reuters, November 2019
• Co-Author, “Examining Octane Fitness Five Years On,” IP Watchdog, April 2019